Biotech Values

[DewDiligence]

We seem to disagree on how well-served the diabetes market is by the array of marketed and late-stage development products from NVO and SNY (among others). You evidently see strong prospects for continued insulin tweaking, while I think the wide array of choices has already reached the point of severely diminishing returns for new aspirants.